SCHEDULE 13G/A: Cormorant Asset Management Discloses 8.57% Stake in Praxis Precision Medicines

Cormorant Asset Management, LP and Bihua Chen have reported a beneficial ownership of 8.57% in Praxis Precision Medicines, Inc. common stock.

Summary

• Cormorant Asset Management, LP and Bihua Chen are the reporting persons for this Schedule 13G/A filing.
• They collectively beneficially own 1,745,000 shares of Praxis Precision Medicines, Inc. common stock.
• This ownership represents 8.57% of the total outstanding common stock of Praxis Precision Medicines, Inc.
• The shares are held with shared voting power and shared dispositive power.
• The percentage of ownership is calculated based on 20,368,982 shares of common stock outstanding as of April 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 2, 2025.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• Cormorant Global Healthcare Master Fund, LP, a Cormorant Fund, holds more than 5% of the shares reported.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment, beyond the neutral act of reporting a significant stake.

Positives

• The disclosure of a significant 8.57% stake by an institutional investor like Cormorant Asset Management, LP, may signal confidence in Praxis Precision Medicines, Inc. to the market.

Future Outlook

NA

Industry Context

This filing is a standard regulatory disclosure by an institutional investor, Cormorant Asset Management, LP, detailing its significant ownership stake in Praxis Precision Medicines, Inc., a company operating in the precision medicines sector. Such disclosures provide transparency on major shareholder positions within the biotechnology and pharmaceutical industries.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and investor confidence.

Key Dates

Keywords

Praxis Precision Medicines, Cormorant Asset Management, Bihua Chen, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing